Generic drugmaker Dr Reddy's Labs … reporting quarter. "Growth in Q2 was driven by momentum in … and R&D The Pharmaceutical Services and Active Ingredients (PSAI … services revenue. R&D expenditure for the quarter stood at …

… Global Generics (GGJ) posted Q2 FY26 revenues of ₹8, … Germany contributed ₹400 crore in Q2 (+23% YoY, +26% QoQ … FY26. Pharmaceutical Services and Active Ingredients (PSAI) posted Q2 FY26 … The company’s capital expenditure for Q2 FY26 was approximately ₹510 …

… October 23, 2025 West Pharmaceutical Services, Inc. beats earnings … European regulators now require pharmaceutical companies to demonstrate their … at the end of Q2 2026. The future available … $210 million in capital expenditures and remain on track for …

… its Q2FY26 earnings. The pharmaceutical firm reported a profit after … operational efficiency. After the Q2 results, here are what … Rs 5,000 crore capital expenditure plan over five years, … citing a better-than-expected Q2 FY26 performance. The brokerage …

The federal government has released an additional ₦32.9 billion through the Basic Health Care Provision Fund, an advancement of the BHCPF 2.0 reform agenda. Oritseweyimi Ogbe, secretary of the Ministerial Oversight Committee, announced this during the 12th …

… therapies, merging antidepressants, pharmacotherapy, and psychotherapy, … Development in Pharmaceuticals: Sun Pharma Secures TGA Approval … fueled by rising healthcare expenditures, increasing postpartum depression … 26.65% CAGR. Q2: Which FDA-approved …

… billion. After a lackluster Q2 compared to rivals Microsoft and … and $72 billion on capital expenditures this year. Earlier this … part of three years. Big Pharma Earnings Novartis (NVS), Eli … Biogen (BIIB) and Alnylam Pharmaceuticals (ALNY) will report Q3 …

… will be balanced between Capital Expenditure (Capex), Mergers & Acquisitions … sustainability reporting contract for a pharma company, providing specialized consulting … QUARTER IN EUR MILLION Q1 Q2 Q3 Marine & … period from Q3 2024 to Q2 2025. 4 TAR: …

… , revenue growth improved over Q2, though it remained down … expands our bioprocessing offering for pharma and biotech, as well … fill-finish network within our pharma services business. At this … it obviously will delay some expenditures by the US government …

… leader in the food and pharmacy industry in Canada. Prior … (188) (165) Net capital expenditure (including new client investments) (484 … the previous year. Net capital expenditure, including client investments, at … ) Fiscal 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2024 …